Ms. Anita Borski, Austria
Anti-IL-6 antibody clazakizumab in late antibody-mediated rejection – Molecular rebound phenomena under IL-6 blockade?

Dr. Stanley Jordan, United States
Clazakizumab (Anti-IL-6 Monoclonal) treatment of patients with chronic & active antibody-mediated rejection post-kidney transplantation (NCT03380377)

Mr. Dominic Amara, United States
Analyzing a pragmatic composite endpoint for 1-year kidney transplant outcomes: Patient loss, graft loss and eGFR less than 30. Results from NSQIP Transplant beta phase

Dr. Manuel Mayrdorfer, Germany
Analyzing causes for death-censored allograft failure in kidney transplant recipients